Gilead Sciences (NASDAQ:GILD) Coverage Initiated at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of Gilead Sciences (NASDAQ:GILD - Free Report) in a research note issued to investors on Tuesday, Marketbeat.com reports. The firm issued an overweight rating and a $125.00 price target on the biopharmaceutical company's stock. Cantor Fitzgerald also issued estimates for Gilead Sciences' FY2025 earnings at $7.93 EPS.

Other research analysts have also issued research reports about the company. DZ Bank raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective for the company in a research report on Thursday, February 13th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Wells Fargo & Company upped their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Finally, Piper Sandler lifted their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. Nine analysts have rated the stock with a hold rating, sixteen have issued a buy rating and four have issued a strong buy rating to the company's stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $108.42.

Gilead Sciences Stock Down 2.8 %

GILD traded down $2.98 during trading on Tuesday, reaching $103.17. The stock had a trading volume of 14,207,970 shares, compared to its average volume of 7,526,289. Gilead Sciences has a one year low of $62.07 and a one year high of $119.96. The company has a market capitalization of $128.46 billion, a price-to-earnings ratio of 278.84, a P/E/G ratio of 0.71 and a beta of 0.32. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock's 50 day moving average is $109.21 and its two-hundred day moving average is $98.15.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.73 by $0.08. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same quarter in the previous year, the firm posted ($1.32) earnings per share. As a group, analysts expect that Gilead Sciences will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 3.06%. The ex-dividend date is Friday, June 13th. Gilead Sciences's payout ratio is 854.05%.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 302,785 shares of company stock valued at $30,540,875 over the last 90 days. 0.27% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of GILD. Westside Investment Management Inc. lifted its holdings in Gilead Sciences by 3.5% in the 3rd quarter. Westside Investment Management Inc. now owns 27,443 shares of the biopharmaceutical company's stock worth $2,249,000 after purchasing an additional 917 shares in the last quarter. SkyView Investment Advisors LLC lifted its holdings in shares of Gilead Sciences by 5.4% in the third quarter. SkyView Investment Advisors LLC now owns 8,482 shares of the biopharmaceutical company's stock worth $711,000 after buying an additional 435 shares in the last quarter. Pine Valley Investments Ltd Liability Co bought a new position in shares of Gilead Sciences during the third quarter worth $209,000. World Investment Advisors LLC grew its position in shares of Gilead Sciences by 33.6% during the third quarter. World Investment Advisors LLC now owns 25,999 shares of the biopharmaceutical company's stock valued at $2,180,000 after purchasing an additional 6,535 shares in the last quarter. Finally, Arvest Bank Trust Division bought a new stake in shares of Gilead Sciences in the third quarter worth about $9,661,000. 83.67% of the stock is owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.